cmsc16

Helius Medical Technologies announced results of a pilot study, demonstrating the benefits of PoNS Therapy — a combination of the investigational Portable Neuromodulation Stimulator (PoNS) device with physical therapy — in patients with advanced multiple sclerosis (MS). Specifically, the treatment was seen to improve both patients’ quality of life, and physical and…

One June 3, a workshop titled “Metabolism in MS and Related Conditions” was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held June 1-4 in National Harbor, Maryland. One of the speakers was Dr. David Sheikh-Hamad, professor of medicine-nephrology at Baylor College of…

There is a greater number of older people with multiple sclerosis than ever before, and the number is likely to continue growing. That combination, of old age with MS, puts people at risk of significantly reduced physical function than those without the disease. This was a key finding of a…

Researchers at Texas Woman’s University identified tai chi as a beneficial therapy for multiple sclerosis (MS) patients with impaired balance, as it can improve their endurance and strength and decrease fatigue. The results of the study, “The Benefit of Tai Chi for Balance and Gait in People with…

Two case reports from the Sheltering Arms Physical Rehabilitation Centers presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting demonstrated how a multiple sclerosis (MS) clinical practice guideline for rehabilitation was implemented through the rehab path, highlighting the importance of consistency of practice and continuity of care for…

Most research in multiple sclerosis (MS) has focused on the impact of the disease on the lower extremities. To balance this, researchers at Mount Sinai Rehabilitation Hospital in Connecticut thoroughly characterized upper arm and hand functions in MS patients, finding that disease duration and disability level differently affected various…

Research from Indiana University School of Medicine showed that D3T – a compound that triggers copying of antioxidant genes and production of the antioxidant glutathione – delays disease development and lowers disease severity in experimental autoimmune encephalomyelitis (EAE) animal models. The models mimicked multiple sclerosis (MS) in humans, advancing further exploration…

MS does not remit and the out dated term causes many people to delay taking medication, says Dr Patricia Coyle, Founder and Director of Stony Brook’s MS Comprehensive Care Center. Dr. Patricia Coyle. Last week, at the CMSC Annual Meeting in Maryland, during a live-streamed presentation covered by Multiple Sclerosis News Today, she…

Results from a Phase 2 clinical trial showed that five-year clinical outcomes of patients with highly active relapsing-remitting multiple sclerosis (RRMS) are significantly improved when patients are treated with high-dose immunosuppressive therapy combined with autologous hematopoietic cell transplantation. The study, “Five-Year Outcomes of Halt-MS: High-
Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell…

Results from the STRIVE study support the safety of natalizumab (Tysabri) as a therapy for multiple sclerosis (MS) patients. The study, “Natalizumab in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: Interim Results from the STRIVE Study,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis…

Newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) show significant improvements when treated with delayed-release dimethyl fumarate (DMF), especially in terms of reduction in confirmed disability progression. The study, “Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Multiple Sclerosis Using a Composite Measure of Disability,” was recently presented at the…

A study, recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting in National Harbor, Md., showed MS patients of African decent might better benefit from treatment with alemtuzumab (Lemtrada) compared to subcutaneous interferon beta-1a (Rebif) – with lower rates of relapses evident over five years…

Dr. Rosalind Kalb, vice president of the Professional Resource Center at the National Multiple Sclerosis Society in New York City, recently presented her work at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) June 1-4 in National Harbor, Maryland. She participated in several symposiums, primarily “Gaining Perspectives on Advanced…

The “Comprehensive Care in MS and Symptom Management” session at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting, included a different kind of contribution –  the presentation of a short film exposing the health challenges specific to Hispanic patients with multiple sclerosis (MS). Intended to promote…

Researchers who looked at manifestations of loneliness found that the burden of loneliness is much higher in multiple sclerosis (MS) patients when compared to healthy people. The study, “Loneliness in Multiple Sclerosis: Putative Antecedents and Manifestations,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) June…

Multiple sclerosis (MS) patients using an interactive, self-guided fatigue management resource, developed by researchers from the University of Alberta in Canada, reported lower fatigue and improved cognition after three months, showing that fatigue self-management tools can contribute to the treatment of this common MS symptom. The pilot study, “…